XPeng Inc. · XPEV · FY2025 Q1 · Calendar Q2 2025
XPeng: AI, new models and overseas expansion raise the bar
The supplied analysis supports a constructive but conditional view: AI integration, new models and international expansion may support growth, but the thesis depends on sustaining volume growth, converting investment into profitability and managing tariff and execution risks.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about XPEV FY2025 Q1
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis emphasizes the next wave of model launches, AI-assisted driving, the Turing chip, the Kunpeng system and faster overseas expansion. It also adds explicit focus on European tariffs, inventory provisions, purchase-commitment losses and the path to profitability.
Guidance delta
Management's guidance sentiment was raised, with Q2 delivery and revenue targets and a Q4 profitability target highlighted in the supplied analysis.
Key takeaways
- Management highlighted AI integration across vehicles and robots, including the Turing chip and a large AI model.
- The product pipeline includes Mona M03 Max, G7 and a next-generation P7, alongside the Kunpeng electric drive system.
- Overseas expansion is focused on China, Europe, the UK, Indonesia and Southeast Asia.
- The supplied analysis identifies tariff, competition, spending and execution risks alongside the growth plan.
Management priorities
- Launch the Mona M03 Max, G7 SUV and next-generation P7.
- Scale the physical-world foundation AI model and its GPU cluster.
- Begin mass production of the Kunpeng electric drive system and expand internationally.
- Advance the humanoid-robot program toward its stated production target.
Follow XPEV with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 17, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Neutral | Overweight | Downgrade | Sep 29, 2026 |
| Barclays | Underweight | Underweight | Maintain | Aug 26, 2026 |
| Macquarie | Outperform | Neutral | Upgrade | May 29, 2026 |
| Freedom Capital Markets | Buy | Hold | Upgrade | Jan 6, 2026 |
| Freedom Broker | Buy | Hold | Upgrade | Jan 6, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 20, 2025 |
| B of A Securities | Buy | Buy | Maintain | Aug 19, 2025 |
| UBS | Neutral | Sell | Upgrade | Feb 24, 2025 |
| China Renaissance | Buy | Hold | Upgrade | Nov 22, 2024 |
| Bernstein | Market Perform | Market Perform | Maintain | Nov 20, 2024 |
| Morgan Stanley | Overweight | Overweight | Maintain | Mar 11, 2024 |
| CLSA | Buy | Outperform | Maintain | Aug 8, 2023 |
| HSBC | Buy | Hold | Upgrade | Aug 7, 2023 |
| Jefferies | Buy | Hold | Upgrade | Jul 28, 2023 |
| BOCOM International | Sell | Neutral | Downgrade | Jul 7, 2023 |
| Daiwa Capital | Sell | Buy | Downgrade | Dec 14, 2022 |
| Nomura Instinet | Neutral | Buy | Downgrade | Jul 1, 2022 |
Named analyst price targets
Upside is calculated against the persisted current price $9.23. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Paul Gong | $12 | $10.93 | +30.0% | Sep 9, 2026 |
| Barclays | Jiong Shao | $14 | $11.15 | +51.7% | Aug 25, 2026 |
| Barclays | Analyst unavailable | $15 | $13.78 | +62.5% | Jul 16, 2026 |
| Jefferies | Alexious Lee | $25.2 | $16.44 | +173.0% | May 29, 2026 |
| Macquarie | Eugene Hsiao | $19 | $16.44 | +105.9% | May 28, 2026 |
| Barclays | Analyst unavailable | $17 | $17.84 | +84.2% | Feb 18, 2026 |
| Macquarie | Eugene Hsiao | $26 | $20.9 | +181.7% | Jan 15, 2026 |
| Loop Capital Markets | Roman Lukianchikov | $25 | $20.14 | +170.9% | Jan 6, 2026 |
| Morgan Stanley | Tim Hsiao | $34 | $26.04 | +268.4% | Nov 11, 2025 |
| Goldman Sachs | Tina Hou | $24 | $18.57 | +160.0% | Jun 17, 2025 |
| Morgan Stanley | Tim Hsaio | $28 | $19.23 | +203.4% | Jun 12, 2025 |
| Bernstein | Eunice Lee | $19 | $20.5 | +105.9% | May 22, 2025 |
| Macquarie | Eugene Hsiao | $24 | $22.25 | +160.0% | May 21, 2025 |
| Bernstein | Analyst unavailable | $18 | $23.8 | +95.0% | Mar 19, 2025 |
| CMB International Securities | Ji Shi | $16 | $12.64 | +73.3% | Nov 20, 2024 |
| Morgan Stanley | Tim Hsiao | $17 | $12.88 | +84.2% | Nov 6, 2024 |
| Citigroup | Jeff Chung | $14.6 | $12.72 | +58.2% | Sep 30, 2024 |
| Citigroup | Jeff Chung | $10.3 | $10.7 | +11.6% | Sep 24, 2024 |
| Macquarie | Eugene Hsiao | $10 | $8.41 | +8.3% | Sep 3, 2024 |
| Citigroup | Jeff Chung | $7.6 | $6.77 | -17.7% | Aug 21, 2024 |
| Barclays | Jiong Shao | $7 | $6.77 | -24.2% | Aug 21, 2024 |
| Daiwa | Kelvin Lau | $11 | $8.1 | +19.2% | May 23, 2024 |
| Bernstein | Eunice Lee | $12 | $8.77 | +30.0% | May 22, 2024 |
| Barclays | Jiong Shao | $8 | $8.77 | -13.3% | May 22, 2024 |
| CFRA | Aaron Ho | $8 | $7.76 | -13.3% | Apr 1, 2024 |
| HSBC | Yuqian Ding | $18.7 | $8.52 | +102.6% | Mar 22, 2024 |
| Morgan Stanley | Tim Hsiao | $18 | $9.89 | +95.0% | Mar 19, 2024 |
| Morgan Stanley | Tim Hsiao | $18.7 | $21.89 | +102.6% | Jul 28, 2023 |
| J.P. Morgan | Analyst unavailable | $9 | $10.09 | -2.5% | Jan 11, 2023 |
| Daiwa | Analyst unavailable | $8 | $10.25 | -13.3% | Dec 14, 2022 |
| HSBC | Analyst unavailable | $15 | $10.47 | +62.5% | Dec 13, 2022 |
| Jefferies | Analyst unavailable | $4.2 | $7.07 | -54.5% | Nov 28, 2022 |
| UBS | Analyst unavailable | $13 | $7.76 | +40.8% | Nov 17, 2022 |
| Citigroup | Analyst unavailable | $27.87 | $18.73 | +202.0% | Aug 24, 2022 |
| Barclays | Jiong Shao | $22 | $18.73 | +138.4% | Aug 23, 2022 |
| Nomura | Martin Heung | $36.3 | $31.74 | +293.3% | Jul 1, 2022 |
| Citigroup | Analyst unavailable | $51.59 | $28.17 | +458.9% | Jun 21, 2022 |
| J.P. Morgan | Analyst unavailable | $35 | $20.8 | +279.2% | May 24, 2022 |
| Barclays | Analyst unavailable | $30 | $20.59 | +225.0% | May 24, 2022 |
| US Tiger Securities | Bo Pei | $40 | $20.76 | +333.4% | May 24, 2022 |
| UBS | Paul Gong | $34 | $25.87 | +268.4% | Apr 18, 2022 |
| Bernstein | Eunice Lee | $56 | $46.24 | +506.7% | Oct 28, 2021 |
| Deutsche Bank | Edison Yu | $51 | $40.28 | +452.5% | Aug 27, 2021 |
| Credit Suisse | Bin Wang | $72 | $43.39 | +680.1% | Aug 2, 2021 |
Track every rating change on XPEV the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationOperating within the People's Republic of China, XPeng Inc. is an innovator in the electric vehicle (EV) sector, focusing on the creation and sale of intelligent, connected automobiles. It handles the entire process from conceptualization to market distribution. Its diverse lineup caters to various consumer needs, featuring SUV models like the G3 and G3i, the P7 performance-oriented sports sedan, and the P5, designed as a family-friendly sedan. Beyond manufacturing vehicles, XPeng supports its customers with a comprehensive ecosystem of services. These encompass sales and financial solutions (including contracts, leasing, and loan referrals), vehicle upkeep (maintenance and super charging), and a range of digital and convenience offerings such as insurance agency, ride-hailing, technical assistance, and music subscriptions. The company was established in 2015, with its headquarters located in Guangzhou, China.
Historical context
All XPEV earningsLatest beats and misses
Who reports nextBeat on EPS
Get the XPEV recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-05-08T09:41:30.427174+00:00
- Polygon adjusted daily market bars · 2026-10-17T21:50:42.560117+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-17T21:50:42.557409+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-17. For educational purposes only; not investment advice.